Steinert R F, Storie B, Smith P, McDonald M B, van Rij G, Bores L D, Colin J P, Durrie D S, Kelley C, Price F, Rostron C, Waring G O, Nordan L T
Center for Eye Research, Harvard Medical School, Boston, Mass, USA.
Arch Ophthalmol. 1996 Feb;114(2):135-41. doi: 10.1001/archopht.1996.01100130129002.
The theoretical benefits of synthetic keratophakia over conventional corneal lamellar procedures are the elimination of donor concerns and superior refractive predictability. Additionally, synthetic material can be inspected for optical quality and power, and it can be sterilized. Furthermore, visual recovery should be more rapid since epithelium is not removed from the central part of the cornea and the need for keratocyte repopulation is eliminated.
To present results on patients who received an intracorneal implant (Kerato-Gel, Allergan Medical Optics, Irvine, Calif) that was made from lidofilcon A, a glucose-permeable hydrogel with an equilibrium water content of 68%.
The intracorneal implants were implanted in 35 adult patients for correction of aphakia. Inclusion criteria excluded patients with aphakia who were candidates for intraocular lenses.
A total of 19 patients were followed up through 2 years postoperatively. For 16 patients with 2-year postoperative refractive data, the average spherical equivalent was -0.63 +/- 2.07 diopters (D). At 2 years, 88% of patients were within +/- 3.00 D of plano and 50% were within +/- 1.00 D. the mean change in Snellen's line for corrected visual acuity was -3.25 lines at 2 years for all patients and -2.0 lines for a subgroup of five patients who were free of vision-limiting preoperative disease.
Results suggest that this intracorneal implant is well tolerated by the cornea and can provide predictable refractive results in patients with high-risk aphakia. Limitations of the procedure are uneven microkeratome resections, loss of best-corrected visual acuity, and irregular astigmatism in some patients. Although these data show good evidence of biocompatibility of the implant material, technical surgical progress is needed to advance this procedure into clinical therapeutic practice.
合成角膜屈光术相较于传统角膜板层手术的理论优势在于消除了供体相关问题以及具有更好的屈光预测性。此外,合成材料可进行光学质量和屈光度检测,并且能够进行消毒。再者,由于未从角膜中央部分去除上皮且无需角膜细胞重新填充,视力恢复应该更快。
呈现接受由lidofilcon A制成的角膜内植入物(角膜凝胶,爱尔康医疗光学公司,加利福尼亚州欧文市)的患者的结果,lidofilcon A是一种平衡含水量为68%的葡萄糖可渗透水凝胶。
将角膜内植入物植入35例成年患者体内以矫正无晶状体眼。纳入标准排除了适合人工晶状体植入的无晶状体眼患者。
共有19例患者术后随访了2年。对于16例有术后2年屈光数据的患者,平均球镜等效度为-0.63±2.07屈光度(D)。在2年时,88%的患者屈光度在±3.00 D范围内,50%的患者在±1.00 D范围内。所有患者矫正视力的Snellen视力表行数平均变化在2年时为-3.25行,对于术前无视力限制疾病的5例患者亚组为-2.0行。
结果表明这种角膜内植入物在角膜中耐受性良好,并且可为高危无晶状体眼患者提供可预测的屈光结果。该手术的局限性在于微型角膜刀切除不均匀、最佳矫正视力下降以及部分患者出现不规则散光。尽管这些数据充分证明了植入材料的生物相容性,但需要手术技术进步才能将该手术推进到临床治疗实践中。